Tests glue injection to reduce leaks after pancreas surgery
Tests N-butyl-2-cyanoacrylate glue injected into pancreas during surgery in adults with pancreatic cancer.
Plain-language title generated from the registry record
Registry title: Saleh's Technique for Pancreaticojejunostomy (Pancreatic Parenchymal Injection of N-butyl-2-cyanoacrylate)
Key facts
- Where
- Minya, EgyptSee the site
- Phase
- Phase 1
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT07132541, who can take part
Where in Egypt
- Liver and GIT hospital , Minia UniversityMinya, EgyptTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Minia University
- Trial code
- NCT07132541
- Record updated
- 11 September 2026
- Original description
This study investigates the safety and efficacy of injecting N-butyl-2-cyanoacrylate (Histoacryl®) into the pancreatic parenchyma during pancreaticoduodenectomy (PD) to enhance the security of the pancreaticojejunostomy (PJ) anastomosis and reduce postoperative pancreatic fistula (POPF) rates.Read full original descriptionShow less
Pancreatic Parenchymal Injection of N-Butyl-2-Cyanoacrylate for Pancreaticojejunostomy After Pancreaticoduodenectomy: A Novel Technique
This study investigates the safety and efficacy of injecting N-butyl-2-cyanoacrylate (Histoacryl®) into the pancreatic parenchyma during pancreaticoduodenectomy (PD) to enhance the security of the pancreaticojejunostomy (PJ) anastomosis and reduce postoperative pancreatic fistula (POPF) rates.
Inclusion: Patients undergoing pancreaticoduodenectomy for malignant lesions meeting the curative treatment intent in accordance with clinical guidelines; Soft pancreatic texture; Small main pancreatic duct diameter (<3 mm); Informed consent obtained.
Exclusion: Patients requiring left, central or total pancreatectomy or other palliative surgery; Patients with vascular invasion and requiring vascular resection; Known hypersensitivity to cyanoacrylate or Lipiodol®; Active infection at the surgical site; Unfit patients for surgery due to severe medical illness; Patients with serious mental disorders; Extremely hard, fibrotic pancreas; Significant pancreatitis involving the pancreatic remnant; Uncontrolled coagulopathy; Inoperable patients with distant metastases, including peritoneal, liver, distant lymph node metastases, and involvement of other organs; Irresectable tumors in diagnostic laparoscopy; Pregnant or breastfeeding women; Patients refused to participate in the study.